Dr Channa Hewamadduma is a Consultant Neuromuscular Neurologist and Honorary Senior Lecturer at University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, UK, where he leads one of the UK’s foremost neuromuscular services, recognised as a centre of clinical and research excellence by Muscular Dystrophy UK. He is internationally recognised for his work across inherited and acquired neuromuscular disorders, with particular expertise in spinal muscular atrophy (SMA), myasthenia gravis, muscular dystrophies, and inflammatory neuropathies such as CIDP and Multifocal Motor Neuropathy.

Dr Hewamadduma serves as National Chief Investigator and Principal Investigator across multiple Phase I–III clinical trials, spanning disease-modifying therapies, advanced therapy medicinal products (ATMPs), and gene therapies. He is a leading investigator in CAR-T cell therapy for myasthenia gravis, one of a small number of such trials globally. At national level, he was a key contributor to inflammatory neuropathy clinical trials such as ADHERE, EMPASSION, iMMERSION, and ARISE together with UK MMN national audit. He has contributed to NICE technology appraisals for nusinersen and risdiplam in SMA, and has led the NHSE commissioning application to designate Sheffield as a UK centre for intrathecal therapies in adult SMA, reflecting Sheffield’s track record delivering complex intrathecal treatments across Yorkshire, Humber, North Derbyshire, and Lincolnshire since 2020.

A founding member of the Adult SMAREACH UK network, Dr Hewamadduma is a key member of the SMA Care UK Steering Group, developing national clinical guidance. He is also a key author of UK national care recommendation update for Myasthenia gravis. He co-chairs the South Yorkshire and Humber Regional Neuromuscular Network and is a founding member of the Adult North Star Network for Duchenne Muscular Dystrophy.

His research programme spans outcome measure development, digital biomarkers, neuroimaging, and translational science using induced neuron cellular modelling for biomarker discovery and compound screening. He has particular expertise in real-world evidence generation in rare neuromuscular disease and has contributed to national policy through NICE and NHSE commissioning guidance for emerging therapies.

Dr Hewamadduma contributes to patient advocacy and rare disease policy at national level and is appointed a Trustee of Myaware (the national charity for myasthenia gravis) and SMA UK. He is a regular invited speaker at national and international neuromuscular conferences and is committed to training the next generation of neuromuscular physicians and allied health professionals.